Aflibercept in Wet AMD Beyond the First Year of Treatment: Recommendations by an Expert Roundtable Panel

This supplement includes recommendations by an expert roundtable panel, London, UK, 5 November 2014. Aflibercept was licensed in Europe for the treatment of wet AMD in November 2012. A national roundtable was convened to discuss UK experience with aflibercept to date, and to use this experience, together with expert opinion, to develop recommendations on the practical application of aflibercept in wet AMD after Year 1. Prescribing information can be found in the appendices. This supplement, and the meeting on which it is based, were sponsored by Bayer HealthCare. All authors received honoraria, contributed to the development of the manuscript, and retained final control of the content and editorial decisions. Medical writing assistance was funded by Bayer HealthCare and provided by AS&K Communications Ltd. Bayer HealthCare checked that the content was factually accurate, balanced, and compliant with the Association of the British Pharmaceutical Industry Code of Practice.